← Back to Search

Monoclonal Antibodies

Bevacizumab for Endometrioid Adenocarcinoma

Phase 2
Waitlist Available
Led By Anil Sood
Research Sponsored by M.D. Anderson Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2 years
Awards & highlights

Study Summary

This trial is testing a first-line treatment of bevacizumab, carboplatin, and paclitaxel for stage III-IV ovarian, primary peritoneal, and fallopian tube cancer.

Eligible Conditions
  • Endometrioid Adenocarcinoma
  • Ovarian Cancer
  • Ovarian Carcinoma
  • Peritoneal Serous Adenocarcinoma
  • Fallopian Tube Cancer
  • Fallopian Tube Carcinoma
  • Ovarian Adenocarcinoma
  • Fallopian Tube Adenocarcinoma
  • Ovarian Brenner Tumor
  • Peritoneal Carcinoma

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 2 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Number of Participants With Treatment Success
Secondary outcome measures
Progression-free Survival of Optimal (RO) </= 1cm (PFS) vs Suboptimal > 1 cm

Trial Design

1Treatment groups
Experimental Treatment
Group I: Treatment (paclitaxel, carboplatin, bevacizumab)Experimental Treatment3 Interventions
Participants receive paclitaxel IV over 3 hours on days 1, 8 and 15 and carboplatin IV over 1 hour on day 1. Beginning course 2, participants also receive bevacizumab IV over 1.5 hours on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Bevacizumab
2013
Completed Phase 4
~5280
Paclitaxel
2011
Completed Phase 4
~5380
Carboplatin
2014
Completed Phase 3
~6670

Find a Location

Who is running the clinical trial?

M.D. Anderson Cancer CenterLead Sponsor
2,971 Previous Clinical Trials
1,787,204 Total Patients Enrolled
National Cancer Institute (NCI)NIH
13,658 Previous Clinical Trials
40,924,514 Total Patients Enrolled
5 Trials studying Endometrioid Adenocarcinoma
1,224 Patients Enrolled for Endometrioid Adenocarcinoma
Anil SoodPrincipal InvestigatorM.D. Anderson Cancer Center

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
First-Line Treatment of Bevacizumab, Carboplatin, and Paclitaxel in Treating Participants With Stage III-IV Ovarian, Primary Peritoneal, and Fallopian Tube Cancer
2010. "First-Line Treatment of Bevacizumab, Carboplatin, and Paclitaxel in Treating Participants With Stage III-IV Ovarian, Primary Peritoneal, and Fallopian Tube Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT01097746.
~2 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top